Live price temporarily unavailable.
Immuneering (IMRX) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $2.31M | $2.08M | $317.0K | $0 | — | — |
| Growth (year over year) | — | −10.0% | −84.8% | −100.0% | — | — |
| Gross profit | $1.03M | $926.9K | $158.8K | $0 | — | — |
| Gross margin | 44.6% | 44.6% | 50.1% | — | — | — |
| Operating income | −$17.1M | −$33.9M | −$51.7M | −$58.4M | −$64.1M | −$59.4M |
| Operating margin | −739.0% | −1629.2% | −16325.8% | — | — | — |
| Net income | −$17.0M | −$33.5M | −$50.5M | −$53.5M | −$61.0M | −$56.0M |
| Net margin | −737.2% | −1612.3% | −15937.3% | — | — | — |
| EPS (diluted) | −$3.44 | −$2.46 | −$1.91 | −$1.88 | −$2.04 | −$1.27 |
| Balance sheet | ||||||
| Cash and equivalents | $37.1M | $74.9M | $72.6M | $59.4M | $36.1M | $128.6M |
| Total assets | $38.4M | $166.7M | $122.4M | $102.6M | $52.7M | $232.0M |
| Total liabilities | $2.80M | $10.7M | $12.5M | $12.0M | $11.3M | $13.5M |
| Shareholders' equity | −$22.5M | $156.0M | $109.9M | $90.6M | $41.4M | $218.5M |
| Cash flow | ||||||
| Operating cash flow | −$14.6M | −$30.9M | −$44.1M | −$49.0M | −$55.0M | −$45.3M |
| Capital expenditure | $53.4K | $60.8K | $742.5K | $342.7K | $84.9K | $142.2K |
| Free cash flow | −$14.7M | −$30.9M | −$44.8M | −$49.3M | −$55.1M | −$45.5M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$15.3M | −$18.6M | −$15.5M | −$14.8M | −$15.4M | −$13.8M | −$15.3M | −$19.0M |
| Net income | −$14.6M | −$18.1M | −$15.0M | −$14.4M | −$15.0M | −$11.6M | −$13.5M | −$17.3M |
| EPS (diluted) | −$0.49 | −$0.59 | −$0.42 | −$0.40 | −$0.38 | −$0.07 | −$0.21 | −$0.27 |
| Balance sheet | ||||||||
| Cash and equivalents | $45.2M | $36.1M | $35.9M | $26.4M | $227.6M | $128.6M | $47.3M | $41.3M |
| Total assets | $68.6M | $52.7M | $50.7M | $40.1M | $241.1M | $232.0M | $214.8M | $202.1M |
| Total liabilities | $10.8M | $11.3M | $8.84M | $11.1M | $13.1M | $13.5M | $8.29M | $11.3M |
| Shareholders' equity | $57.7M | $41.4M | $41.8M | $28.9M | $228.0M | $218.5M | $206.5M | $190.7M |
| Cash flow | ||||||||
| Operating cash flow | −$13.5M | −$14.5M | −$14.1M | −$9.45M | −$12.0M | −$9.84M | −$18.4M | −$16.5M |
| Capital expenditure | $5.27K | $9.36K | $8.95K | $2.12K | $7.25K | $123.9K | $79.9K | $27.4K |
| Free cash flow | −$13.5M | −$14.5M | −$14.1M | −$9.45M | −$12.0M | −$9.96M | −$18.5M | −$16.5M |
From Immuneering's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Immuneering in our feed yet.